Pfizer delays Exubera launch

Share this article:
Pfizer said it would delay the launch of its inhaled insulin Exubera until early September, weeks later than its previously anticipated delivery date of mid-July. Pfizer executives said Thursday in a conference call with analysts the delay is a result of wanting to make sure US educational programs for doctors, pharmacists and diabetes educators are properly conducted. “We will never get a second chance,” to introduce Exubera, said Pfizer CEO Hank McKinnell. Pfizer vice chair of human-health, Karen Katen, said, “our education programs and manufacturing preparations are time consuming but we are taking the time necessary to do the job right. We are working not only to meet initial demand for the medicine but also continued demand from prescription refills. Initial supplies of Exubera will be available across the US beginning in September.” Peter Brandt, SVP of global pharmaceuticals said manufacturing of Exubera will be coordinated with the progress of the education program. Pfizer is expected to be providing Exubera starter kits to doctors who are heavy prescribers of insulin, beginning next week. Exubera was approved by the FDA in January and made available in Germany and Ireland in May. Company officials told analysts they did not have enough information on sales in the two European nations to assess Exubera’s progress so far.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...